【3 月 31 日,信达生物制药集团透露,其全球首创 PD-1/IL-2α-bias 双特异性抗体融合蛋白 IBI363 已被中国国家药品监督管理局纳入突破性治疗药物品种名单。】拟定适应症为既往未经过系统性治疗的不可切除局部晚期或转移性肢端型及黏膜型黑色素瘤。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.